{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:11:09Z","timestamp":1753881069691,"version":"3.41.2"},"reference-count":26,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3\/4A (NS3\/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection. The pharmacokinetics, pharmacodynamics, safety, and tolerability of methadone or buprenorphine-naloxone when coadministered with the glecaprevir-pibrentasvir combination in HCV-negative subjects on stable opioid maintenance therapy were investigated in a phase 1, single-center, two-arm, multiple-dose, open-label sequential study. Subjects received methadone (arm 1) or buprenorphine-naloxone (arm 2) once daily (QD) per their existing individual prescriptions alone (days 1 to 9) and then in combination with glecaprevir at 300 mg QD and pibrentasvir at 120 mg QD (days 10 to 16) each morning. Dose-normalized exposures were similar with and without glecaprevir and pibrentasvir for (\n            <jats:italic>R<\/jats:italic>\n            )- and (\n            <jats:italic>S<\/jats:italic>\n            )-methadone (\u22645% difference) and for buprenorphine and naloxone (\u226424% difference); the norbuprenorphine area under the curve was 30% higher with glecaprevir and pibrentasvir, consistent with maximum and trough plasma concentrations that increased by 21% to 25%. No changes in pupil response, short opiate withdrawal scale score, or desire for drugs questionnaire were observed when glecaprevir and pibrentasvir were added to methadone or buprenorphine-naloxone therapy. No dose adjustment is required when glecaprevir and pibrentasvir are coadministered with methadone or buprenorphine-naloxone.\n          <\/jats:p>","DOI":"10.1128\/aac.00958-17","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T00:40:16Z","timestamp":1502757616000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir"],"prefix":"10.1128","volume":"61","author":[{"given":"Matthew P.","family":"Kosloski","sequence":"first","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihan","family":"Zhao","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Geoffroy","sequence":"additional","affiliation":[{"name":"INC Research, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. July2016. Hepatitis C fact sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. Accessed 18 April 2016."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_3_2_5_2","first-page":"132A","article-title":"ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493\/ABT-530 in patients with chronic HCV genotype 1 infection, abstr 253","volume":"64","author":"Zeuzem S","year":"2016","unstructured":"Zeuzem S FeldJJ WangS BourliereM WedemeyerH GaneEJ FlisiakR ChuangW-L FlammSL KwoPY SepulvedaG Soto-MalaveR PuotiM TamE BruckR FusterF PaikSW FelizartaF FuB NgT LinC-W MensaF. 2016. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493\/ABT-530 in patients with chronic HCV genotype 1 infection, abstr 253. Hepatology64(Suppl):132A.","journal-title":"Hepatology"},{"key":"e_1_3_2_6_2","first-page":"39A","article-title":"ENDURANCE-2: safety and efficacy of ABT-493\/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study, abstr 73","volume":"64","author":"Kowdley KV","year":"2016","unstructured":"Kowdley KV ColomboM ZadeikisN MantryPS CalinasF AguilarHI de LedinghenV HorsmansYJ HuY NgT MensaF. 2016. ENDURANCE-2: safety and efficacy of ABT-493\/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study, abstr 73. Hepatology64(Suppl):39A.","journal-title":"Hepatology"},{"key":"e_1_3_2_7_2","first-page":"63A","article-title":"ENDURANCE-4: efficacy and safety of ABT-493\/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection, abstr 114","volume":"64","author":"Asselah T","year":"2016","unstructured":"Asselah T HezodeC ZadeikisN ElkhashabM ColomboM MarinhoRT AgarwalK NevensF LiuR NgT MensaF. 2016. ENDURANCE-4: efficacy and safety of ABT-493\/ABT-530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection, abstr 114. Hepatology64(Suppl):63A.","journal-title":"Hepatology"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.91.1.46"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1133"},{"key":"e_1_3_2_10_2","unstructured":"Weaver\nMF HopperJA. 2011. Treatment of opioid use and dependence. In BasowDS (ed) UpToDate. http:\/\/cursoenarm.net\/UPTODATE\/contents\/mobipreview.htm?26\/33\/27153?source=see_link."},{"key":"e_1_3_2_11_2","volume-title":"Suboxone\u00ae (buprenorphine and naloxone sublingual film) package insert","author":"Indivor, Inc","year":"2011","unstructured":"Indivor, Inc. 2011. Suboxone\u00ae (buprenorphine and naloxone sublingual film) package insert. Indivor, Inc, Richmond, VA. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022410s020s022lbl.pdf."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03374.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02079.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2008.01597.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S0168-8278(16)00642-5","article-title":"ABT-493 and ABT-530 combination demonstrated minimal potential for CYP-mediated drug-drug interactions","volume":"64","author":"Kosloski MP","year":"2016","unstructured":"Kosloski MP DuttaS PugatchD LiH MensaF KortJ LiuW. 2016. ABT-493 and ABT-530 combination demonstrated minimal potential for CYP-mediated drug-drug interactions. J Hepatol64(Suppl):S405.","journal-title":"J Hepatol"},{"key":"e_1_3_2_16_2","first-page":"818","article-title":"Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4","volume":"26","author":"Kobayashi K","year":"1998","unstructured":"Kobayashi K YamamotoT ChibaK TaniM ShimadaN IshizakiT KuroiwaY. 1998. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos26:818\u2013821.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318238fea0"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/187231209788654117"},{"key":"e_1_3_2_19_2","first-page":"688","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang P","year":"2001","unstructured":"Huang P KehnerGB CowanA Liu-ChenLY. 2001. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther297:688\u2013695.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.004333"},{"key":"e_1_3_2_21_2","volume-title":"Abstr Conf Retroviruses Opportunistic Infections","author":"Kosloski MP","year":"2016","unstructured":"Kosloski MP DuttaS DingB WangS KortJ LiuW OberoiRK. 2016. Interactions between ABT-493 plus ABT-530 combination and rilpivirine or raltegravir, abstr 453. Abstr Conf Retroviruses Opportunistic Infections, abstr 453. http:\/\/www.croiconference.org\/sessions\/interactions-between-abt-493-plus-abt-530-combination-and-rilpivirine-or-raltegravir."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00478-15"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0950-3528(88)90024-3"},{"key":"e_1_3_2_24_2","volume-title":"High SVR rates with eight and twelve weeks of pangenotypic glecaprevir\/pibrentasvir: integrated efficacy analysis of genotype 1 to 6 patients without cirrhosis (SAT-233)","author":"Puoti M","year":"2017","unstructured":"Puoti M FosterGR WangS MutimerD GaneE MorenoC ChangTT LeeS MarinhoR DuFourJ-F PolS HezodeC GordonSC StrasserSI ThuluvathPJ LiuR Pilot-MatiasT MensaF. 2017. High SVR rates with eight and twelve weeks of pangenotypic glecaprevir\/pibrentasvir: integrated efficacy analysis of genotype 1 to 6 patients without cirrhosis (SAT-233). Poster presented at the International Liver Congress, 19 to 23 April 2017, Amsterdam, The Netherlands."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.13"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(90)90036-W"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(01)00201-5"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00958-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00958-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:46:05Z","timestamp":1645476365000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00958-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1128\/AAC.00958-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.00958-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2017-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00958-17"}}